Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of “Hold” from Brokerages

Moderna, Inc. (NASDAQ:MRNA) has received a consensus rating of “Hold” from the twenty-one analysts that are presently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a sell recommendation, eleven have assigned a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $79.50.

MRNA has been the topic of a number of research reports. Royal Bank of Canada reissued a “sector perform” rating and set a $75.00 target price on shares of Moderna in a report on Thursday, September 19th. Leerink Partners reduced their price objective on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a research note on Tuesday, September 17th. Sanford C. Bernstein started coverage on Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price for the company. Jefferies Financial Group reduced their price target on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Tuesday, October 15th. Finally, Berenberg Bank assumed coverage on Moderna in a research report on Tuesday, November 19th. They set a “hold” rating and a $42.00 price objective for the company.

Insiders Place Their Bets

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,379 shares of company stock worth $158,195. 15.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Inspire Trust Co. N.A. increased its position in shares of Moderna by 73.5% during the third quarter. Inspire Trust Co. N.A. now owns 16,525 shares of the company’s stock worth $1,104,000 after acquiring an additional 7,000 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its holdings in Moderna by 1.4% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 287,887 shares of the company’s stock worth $19,239,000 after purchasing an additional 3,978 shares in the last quarter. Toronto Dominion Bank raised its stake in shares of Moderna by 23.7% in the third quarter. Toronto Dominion Bank now owns 131,477 shares of the company’s stock worth $8,787,000 after purchasing an additional 25,177 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Moderna by 2.6% in the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after purchasing an additional 178,115 shares in the last quarter. Finally, Groupama Asset Managment boosted its position in shares of Moderna by 29.1% during the third quarter. Groupama Asset Managment now owns 21,838 shares of the company’s stock valued at $1,459,000 after buying an additional 4,920 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Down 2.6 %

Shares of MRNA opened at $40.76 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna has a 52 week low of $35.80 and a 52 week high of $170.47. The stock has a market capitalization of $15.69 billion, a price-to-earnings ratio of -7.18 and a beta of 1.58. The stock has a fifty day moving average of $47.92 and a 200-day moving average of $82.45.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the company earned ($1.39) earnings per share. As a group, sell-side analysts anticipate that Moderna will post -9.3 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.